[Glasgow, Scotland – Tuesday, 6th May, 2025] We’re pleased to share that PneumoWave has received Class II FDA 510(k) clearance for our Data Collection Mobile (DCM) system – a significant...
Read More
Welcome to PneumoWave, where we are revolutionizing how we address the critical issue of opioid-induced respiratory depression (OIRD). By harnessing the potential of advanced data analytics, we empower timely interventions that can save lives and prevent respiratory distress.
Welcome to PneumoWave, where we are revolutionizing how we address the critical issue of opioid-induced respiratory depression (OIRD). By harnessing the potential of advanced data analytics, we empower timely interventions that can save lives and prevent respiratory distress.
PneumoWave is an integrated platform of patient data capture and proprietary analysis.
Our solutions aim to facilitate a paradigm shift in respiratory care focusing on intervention before disease or injury has advanced.
24/7 Repiratory Monitoring
Our small, chest-worn biosensor continuously captures data and transmits it wirelessly for analysis.
Real-time Results
Proprietary algorithms aim to accurately detect a range of respiratory adverse events in real-time.
Cloud Platform
Processed data can be viewed in our cloud platform, allowing clinicians to remotely provide personalized treatment.
Alert System
Our alert system promptly notifies healthcare providers of potential respiratory distress, enabling timely interventions.
24/7 Repiratory Monitoring
Our small, chest-worn biosensor continuously captures data and transmits it wirelessly for analysis.
Cloud Platform
Processed data can be viewed in our cloud platform, allowing clinicians to remotely provide personalized treatment.
PneumoWave is an integrated platform of patient data capture and proprietary analysis.
Our solutions aim to facilitate a paradigm shift in respiratory care focusing on intervention before disease or injury has advanced.
Real-time Results
Proprietary algorithms aim to accurately detect a range of respiratory adverse events in real-time.
Alert System
Our alert system promptly notifies healthcare providers of potential respiratory distress, enabling timely interventions.
Towards the end of the 20th century, misleading information by several pharmaceutical companies, claiming their opioid painkillers were non-addictive, triggered a surge in prescriptions across the United States for individuals with chronic pain.
At the same time, the increased availability of opioids created a concerning trend, as individuals with emotional trauma and mental health conditions sought solace in these drugs, chasing the temporary euphoria they provided and unknowingly falling into rapid dependency.
Today, the misuse of prescription and illicit opioids is the leading cause of death in most developed nations. Within the United States alone, it has evolved into a public health emergency, claiming the lives of over 70,000 individuals last year (CDC).
From 1999-2019
Involving both prescription & illicit opioids
£5.2 m equity from Scottish National Investment Bank alongside £2.3 m from existing investors Scottish Enterprise, IIG, London & Scottish…
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform in a clinical trial led by Professor Sir John Strang at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
Press Release
January 19, 2022
Tuesday 2nd November Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the commencement of a second clinical…
Press Release
November 2, 2021
[Glasgow, Scotland – Tuesday, 6th May, 2025] We’re pleased to share that PneumoWave has received Class II FDA 510(k) clearance for our Data Collection Mobile (DCM) system – a significant...
Read More[Glasgow, Scotland – Thursday 31st October, 2024] https://www.gov.uk/government/news/virtual-reality-and-wearable-technology-pilot-to-cut-drug-deaths Government awards £12 million to research projects across the UK that are researching innovative technology to support people with addictions. PneumoWave are...
Read More[Glasgow, Scotland – Monday 23rd September, 2024] https://www.researchprotocols.org/2024/1/e57367 A joint paper was published in JMIR Research Protocols, vol 13 (2024), detailing the OD-SEEN (Overdose Sensor Detection amongst high-risk opioid users...
Read More
Please contact us with any enquiries. We will aim to respond to your query as soon as possible.
PneumoWave, LTD
Suites 3 and 4
Second Floor, Maxim 3
Maxim Office Park
Parklands Avenue
Eurocentral ML1 4WQ
UK
PneumoWave, Inc.
4900 O’Hear Avenue, Suite 100
North Charleston, SC 29405
USA
421 Fayetteville Street,
Suite 1100,
Raleigh, NC 27601
USA
Welcome to PneumoWave, where we are revolutionizing how we address the critical issue of opioid-induced respiratory depression (OIRD). By harnessing the potential of advanced data analytics, we empower timely interventions that can save lives and prevent respiratory distress.
PneumoWave is an integrated platform of patient data capture and proprietary analysis.
Our solutions aim to facilitate a paradigm shift in respiratory care focusing on intervention before disease or injury has advanced.
24/7 Repiratory Monitoring
Our small, chest-worn biosensor continuously captures data and transmits it wirelessly for analysis.
Real-time Results
Proprietary algorithms aim to accurately detect a range of respiratory adverse events in real-time.
Cloud Platform
Processed data can be viewed in our cloud platform, allowing clinicians to remotely provide personalized treatment.
Alert System
Our alert system promptly notifies healthcare providers of potential respiratory distress, enabling timely interventions.
£5.2 m equity from Scottish National Investment Bank alongside £2.3 m from existing investors Scottish Enterprise, IIG, London & Scottish…
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform in a clinical trial led by Professor Sir John Strang at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.
Press Release
January 19, 2022
Tuesday 2nd November Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the commencement of a second clinical…
Press Release
November 2, 2021
View our list of open positions below. Please do not hesitate to contact us with any questions about your application.